Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Código da empresaASRT
Nome da EmpresaAssertio Holdings Inc
Data de listagemFeb 12, 1997
CEOReisenauer (Mark L)
Número de funcionários58
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 12
Endereço100 S. Saunders Road
CidadeLAKE FOREST
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal60045
Telefone12244197106
Sitehttps://www.assertiotx.com/
Código da empresaASRT
Data de listagemFeb 12, 1997
CEOReisenauer (Mark L)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados